Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Switch to Aromasin Maintains QOL of Breast Cancer Patients: IES Study
March 6, 2006
- Pfizer Japan to Appoint New President & CEO
March 6, 2006
- R&D NEWS IN BRIEF
March 6, 2006
- GSK to Participate in Vaccine Business in Japan
March 6, 2006
- MEDICAL DEVICE NEWS IN BRIEF
March 6, 2006
- MPC, Lequio Pharma License Zione to Yuhan of South Korea
March 6, 2006
- 47 Chemotherapy Specialists to Be Certified by JSMO in April
March 6, 2006
- Chugai Licenses Conditionally Immortalized Cell Line from Cambrex
March 6, 2006
- NEW BOOKS
March 6, 2006
- Kyowa Hakko Licenses Parkinson's Treatment from Britannia
March 6, 2006
- Japanese Branch of RAPS Established
March 6, 2006
- Fresenius to Complete Seamless Production System for Dialyzers in Japan
February 27, 2006
- Korosho's NHI Pricing Reform Proposals Approved
February 27, 2006
- GSK Distributes Asthma Control Test to Physicians for Use by Patients
February 27, 2006
- JGPMA Holds Symposium, Panel Discussion on GE Drug Quality
February 27, 2006
- R&D NEWS IN BRIEF
February 27, 2006
- Nearly All Dispensing Pharmacies Handle Generic Drugs: Survey
February 27, 2006
- PMDA Providing More Multiple Preliminary Interviews
February 27, 2006
- 33% of Patients Requested Generic Substitution, 18% Received Generics: Survey
February 27, 2006
- Systems Drug Discovery Should Replace Probabilistic Drug Discovery: Prof. Tanuma
February 27, 2006
ページ
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…